Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types
- Anti-p53 antibodies are antibodies that mistakenly target a patient's own tissues, leading to a growth of solid tumors.
- Screening for Anti-p53 helps to diagnose throat, bowel and breast cancers earlier, thereby increasing the chances that a patient responds to a treatment
- The Elecsys Anti-p53 could be used to monitor cancer cell remnants in the patient’s body
Basel, 07 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. This test is used to aid physicians to diagnose throat cancer, bowel cancer and breast cancer in patients, in conjunction with other diagnostic tests. The assay is now available for all markets accepting the CE Mark.
“The addition of our Elecsys Anti-p53 immunoassay will help clinicians to quickly and reliably diagnose several prevalent cancers and might assist in leading to a better prognosis for many patients.”, said Thomas Schinecker, CEO Roche Diagnostics. “Beyond breakthrough cancer medicines, Roche also offers a growing number of testing solutions to help physicians diagnose and treat people with cancer.
p53 is protein which, when active, helps to regulate processes which stop tumors from developing. A mutation of p53 is present in half of solid tumor cancers and is the most common genetic change identified so far in human cancers.1 Certain mutations of p53 can lead to a build up of p53 which results in the formation of anti-p53 autoantibodies. Autoantibodies are antibodies that mistakenly target and react with a person’s own tissues. Between 20-50% of patients with mutated p53 will produce anti-p53 autoantibodies.2 This mutation causes the tumor suppressive function of p53 to switch to a tumor-promoting function and thus cancer development.
Early appearance of anti-p53 antibodies during tumour development may have potential to detect malignant changes.3 The Elecsys Anti-p53 immunoassay detects these anti-p53 antibodies and, when used with other diagnostic tests, can help to diagnose certain cancers, at an earlier stage, which may help to improve patient outcomes. Determining the presence of anti-p53 antibodies may also be useful for monitoring cancerous cells that are still in the body following treatment.4 In addition, the Elecsys Anti-p53 test could aid in determining which patients may require less invasive treatment procedures, as part of their cancer treatment.
About Elecsys Anti-p53
Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 autoantibodies in human serum and plasma. Elecsys Anti-p53 is a high precision immunoassay, with a low turn-around time for testing, complementing our overall tumor marker portfolio. The new Elecsys Anti-p53 immunoassay uses the well-established electrochemiluminescence immunoassay “ECLIA” technology and is intended for use on cobas e immunoassay analyzers.
For further information on Elecsys immunoassays visit here.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 Yue X, et al. J Mol Biol 2017;429:1595-606
 Suppiach et al. World J Gastroenterol 2013 August 7; 19(29): 4651-4670
 Soussi T. Cancer Res 2000;60:1777-88
 Kastenhuber E & Lowe S. Cell 2017;170(6):1062-78
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
|Dr. Nicolas Dunant|
Phone: +41 61 687 05 17
Phone: +41 61 688 44 86
|Dr. Daniel Grotzky |
Phone: +41 61 688 31 10
Phone: +41 61 682 28 31
Phone: +41 79 327 54 74
Phone: +41 61 687 43 05
|Dr. Barbara von Schnurbein|
Phone: +41 61 687 89 67
|Roche Investor Relations|
|Dr. Karl Mahler|
Phone: +41 61 68-78503
|Jon Kaspar Bayard|
Phone: +41 61 68-83894
|Dr. Sabine Borngräber|
Phone: +41 61 68-88027
|Dr. Bruno Eschli|
Phone: +41 61 68-75284
|Dr. Birgit Masjost|
Phone: +41 61 68-84814
|Dr. Gerard Tobin|
Phone: +41 61 68-72942
|Investor Relations North America|
Phone: +1 650 225 3217
|Dr. Lisa Tuomi|
Phone: +1 650 467 8737
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Notification according to chapter 9, section 10 of the Securities Market Act: Bolero Holdings SARL ownership in Suominen decreases to below 5 percent16.4.2021 15:30:00 CEST | Press release
Suominen Corporation, stock exchange release on April 16, 2021 at 4.30 p.m. (EET). Suominen Corporation has on April 16, 2021 received a notification referred to in Chapter 9, Section 5 and 6 of the Securities Market Act. According to the notification, the shareholding of Bolero Holdings SARL in Suominen Corporation has fallen below the 5% flagging threshold. Total positions of person subject to the notification obligation: % of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in % (7.A + 7.B)Total number of shares and voting rights of the issuerResulting situation on the date on which threshold was crossed or reachedBelow 5%n/aBelow 5%58,259,219Position of previous notification (if applicable)5.81%n/a5.81% Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rightsClass/type of sharesNumber of shares and voting rights% of shares and votin
Correction: REGARDING DRAFT ALTERNATIVE RESOLUTION SUBMITTED TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS16.4.2021 14:49:32 CEST | Press release
Correction: the number of shares indicated – 380.396.585 and declared dividends per share – 0,0198 EUR. On 15 April 2021 AB “Klaipėdos nafta” (hereinafter – Company) received a proposal from the Ministry of Energy of the Republic of Lithuania (hereinafter referred to as the Shareholder), that executes the rights of the Shareholder – the Republic of Lithuania that owns 275 687 444 ordinary registered shares, making 72,45 per cent of the total amount of the Company’s shares, on an alternative draft resolution of the issue on the agenda of the ordinary registered meeting of shareholders of the Company to be convened on 30 April 2021. Following paragraphs 3, 4 and 5 of Article 25 of the Law on Companies of the Republic of Lithuania, the Shareholder as the person exercising the right to propose draft resolutions of the Company’s General Meeting, holding shares that grant at least 1/20 of all the votes, proposes to approve the following draft resolution of the fourth item on the agenda of th
Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)16.4.2021 14:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 16 April 2021 at 3:30 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 15 April 2021 above five (5) per cent of Sampo plc’s total voting rights. In addition, the disclosure obligation arose due to the number of Sampo A shares owned directly or indirectly by BlackRock, Inc. and its funds increasing above 5 per cent. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions
CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 1016.4.2021 12:45:00 CEST | Press release
Allentown, April 16, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 10 ALLENTOWN, PA, April 16, 2021 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its first quarter 2021 results after the market closes on Monday, May 10, 2021. In conjunction with the news release, management will host a conference call on Tuesday, May 11, at 9:00 a.m. Eastern Time. The conference call numbers are 800-774-6070 or 630-691-2753 and the passcode for both is 7265208#. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor section of the CrossAmerica website (www.crossamericapartners.com). To listen to the audio webcast, go to https://caplp.gcs-web.com/webcasts-presentations https://caplp.gcs-web.com/webcasts-presentations. A
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD16.4.2021 11:00:00 CEST | Press release
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression. Oladele Adebogun M.D. said, “I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the number of pat
RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS16.4.2021 10:08:23 CEST | Press release
Auction date2021-04-16Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 400Volume offered, SEK mln4,000Volume bought, SEK mln750Number of bids12Number of accepted bids3Average yield0.367 %Lowest accepted yield0.367 %Highest yield0.368 %% accepted at lowest yield 65.00 Auction date2021-04-16Loan1053Coupon3.50 %ISIN-codeSE0002829192Maturity2039-03-30Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,400Volume bought, SEK mln500Number of bids5Number of accepted bids2Average yield0.696 %Lowest accepted yield0.693 %Highest yield0.698 %% accepted at lowest yield 100.00 Auction date2021-04-16LoanREGS Kingdom of SwedenCoupon0.125 %ISIN-codeXS2226974504Maturity2030-09-09Tendered volume, SEK mln250 +/- 250Volume offered, SEK mln600Volume bought, SEK mln250Number of bids6Number of accepted bids3Average yield0.287 %Lowest accepted yield0.281 %Highest yield0.291 %% accepted at lowest yield 50.00
Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®16.4.2021 09:00:00 CEST | Press release
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy. The trial is originated by the principal investigator of the trial, Dr Michael Häggman, Associate Professor at the Department of Surgical Sciences in Urology, Uppsala University Hospital. The study is planned to start in mid of this year and it will enroll 10- 15 patients to be treated with NZ-DTX prior to planned surgery. “The NanoZolid technology is suitable to combine with the MRI/TRUS injection technique for a high precision intratumoral delivery of NZ-DTX Depot. Treating patients prior to removal of the prostate gland will provide exhaustive information with regards to local effects in the tumor and surrounding tissue”, commented Dr Michael Häggman. “We are very pleased